SCHEDULE: Invus Group Affiliates Maintain 1.5% Stake in Kalaris Therapeutics
Beneficial Ownership Disclosure
Invus Public Equities and its affiliated entities, including Invus Public Equities Advisors, Invus Global Management, Siren, and Raymond Debbane, continue to collectively hold a 1.5% beneficial ownership in Kalaris Therapeutics, Inc.
Summary
- Invus Public Equities, L.P. and its related entities, including Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and Raymond Debbane, collectively beneficially own 282,586 shares of Kalaris Therapeutics, Inc. Common Stock.
- This ownership represents 1.5% of the total outstanding shares of Kalaris Therapeutics, Inc.
- The calculation of the percentage of shares beneficially owned is based on 18,702,418 shares outstanding as of June 25, 2025, as reported by the Issuer in its Form DEF14A filed on July 1, 2025.
- The reporting persons, including Invus Public Equities, L.P. (Bermuda), Invus Public Equities Advisors, LLC (Delaware), Invus Global Management, LLC (Delaware), Siren, L.L.C. (Delaware), and Raymond Debbane (Panama), each hold sole voting and sole dispositive power over the 282,586 shares.
Sentiment
Score: 5
Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 3) and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects. It simply updates the public record on an existing investment stake.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an institutional investor group in a biotechnology company. It does not provide specific insights into Kalaris Therapeutics' operational performance or broader industry trends, but rather reflects an ongoing investment position.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership stake held by a significant institutional investor group, confirming their continued, albeit small, position in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-06-25 | Date on which the number of outstanding shares (18,702,418) was reported by the Issuer in its Form DEF14A. |
| 2025-06-30 | Date of event which requires the filing of this statement, reflecting the beneficial ownership. |
| 2025-07-01 | Date Kalaris Therapeutics, Inc. filed its Form DEF14A with the SEC, providing the outstanding share count. |
| 2025-07-29 | Date the Schedule 13G Amendment No. 3 was signed by Raymond Debbane on behalf of all reporting persons. |
Keywords
Kalaris Therapeutics, Invus Public Equities, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Shareholding, Allovir
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.